A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401)

BACKGROUND: Metastatic sarcoma patients have limited options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We evaluated the efficacy and safety of nivolumab and nivolumab plus ipilimumab separately in sarcoma patients. METHODS: We did an open-label, unb...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: D’Angelo, Sandra P., Mahoney, Michelle R., Van Tine, Brian A., Atkins, James, Milhem, Mohammed M., Jahagirdar, Balkrishna N., Antonescu, Cristina R., Horvath, Elise, Tap, William D., Schwartz, Gary K., Streicher, Howard
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6126546/
https://ncbi.nlm.nih.gov/pubmed/29370992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30006-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados